Tiziana Life Sciences Ltd (TLSA) NASDAQ
1.36
-0.04(-2.86%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Tiziana Life Sciences Ltd
Address
55 Park Lane
London, W1K 1NA
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 20 7495 2379
Sector
Healthcare
Industry
Biotechnology
Employees
9
First IPO Date
November 20, 2018
Key Executives
| Name | Title | Pay | Year Born |
| Ivor R. Elrifi | Chief Executive Officer & Executive Director | 131,000 | N/A |
| Napoleone Ferrara | Member of Scientific Advisory Board | 0 | 1957 |
| Richard K. Kim | Chief Medical Officer | 0 | 1971 |
| William Edward Tente | Chief Regulatory Officer | 0 | 1958 |
| Keeren Shah | Chief Operating Officer & Chief Financial Officer | 0 | 1976 |
| Gabriele Marco Antonio Cerrone | Founder & Executive Chairman | 0 | 1972 |
Description
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
